FOR IBSA ITALIA, INNOVATION IS A DAILY CHALLENGE AND THE FOCAL POINT OF ALL ACTIVITIES.
It stems from the intuition of wanting to transform the therapeutic solutions available into a more advanced treatment tool that responds to patients’ real needs, thereby improving people’s quality of life. It is precisely this intuition that has transformed the company into a leading economic, scientific and industrial reality in the Italian pharmaceutical sector, active in over 10 therapeutic areas.
One of the main therapeutic areas is the osteoarticular field, a segment in which IBSA occupies an important position. Thanks to major and continuous investment in research and development activity, IBSA is able to offer solutions that use innovative, patented technologies. These include transdermal medicated plasters with hydrogel and drug-in-adhesive technologies, biofermentative and Shyalth ultrapure hyaluronic acid for intra-articular use.
The focus on continuous innovation at the service of patients has also led to the launch of a gel based on diclofenac, an effective and rapid solution against osteoarticular and traumatic pain. The gel is produced by IBSA in Italy in an exclusive airless bottle, which guarantees optimal preservation and delivery down to the last drop. The innovative formula, with soy lecithin nanoparticles, favours rapid absorption of the active ingredient, making the gel fast and more effective against pain and inflammation.